FDA expands meningitis vaccine age range

Oct 18, 2007

The U.S. Food and Drug Administration has expanded the approved age range for Menactra, a bacterial meningitis vaccine.

Originally approved by the FDA in 2005 for use by people ages 11 to 55 years, it is now approved to include children ages 2 to 10 years.

Meningitis is a serious inflammation of the lining that surrounds the spinal cord and brain and can result in death or permanent injury.

Before Menactra's approval, Menomune was the only meningococcal vaccine available in the United States for use in children, ages 2 years and older. Both products are manufactured by Sanofi Pasteur Inc. of Swiftwater, Pa., and both offer protection against four groups of Neisseria meningitidis, the bacterium that can cause meningitis.

The Centers for Disease Control and Prevention recommends meningococcal vaccination for children ages 2 to 10 years who are at increased risk of meningococcal disease, such as those whose spleen has been removed; those with a medical condition that makes it difficult to fight infection; and those who expect to travel to areas where the disease is common.

Vaccination also is used to control outbreaks of bacterial meningitis.

Copyright 2007 by United Press International

Explore further: New treatment approved for rare form of hemophilia

add to favorites email to friend print save as pdf

Related Stories

Tablets, cars drive AT&T wireless gains—not phones

9 hours ago

AT&T says it gained 2 million wireless subscribers in the latest quarter, but most were from non-phone services such as tablets and Internet-connected cars. The company is facing pricing pressure from smaller rivals T-Mobile ...

Twitter looks to weave into more mobile apps

10 hours ago

Twitter on Wednesday set out to weave itself into mobile applications with a free "Fabric" platform to help developers build better programs and make more money.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0